Sun Pharma Advanced Research Co

About the company

Sun Pharma Advanced Research Company Ltd. (SPARC) is an India-based clinical-stage biopharmaceutical company focused on developing new drugs and delivery systems. It specializes in creating therapeutics in oncology, neurology, and immunology. SPARC's key projects include vodobatinib for chronic myelogenous leukemia and neurodegenerative diseases, an anti-MUC-1 antibody-drug conjugate for multiple cancers, vibozilimod for autoimmune disorders, and SCD-153 for alopecia areata. The company engages in licensing agreements and partnerships for commercialization of its products. SPARC has received FDA approvals for some of its drugs, including XELPROS for glaucoma treatment. The company was incorporated in 2006 and operates independently after demerging from Sun Pharmaceutical Industries Ltd.